Current approaches for neoadjuvant chemotherapy in breast cancer

European Journal of Pharmacology

Volumn 717, Issue 1-3, 2013, Pages 58-66

  Connolly, Roisin M ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarkers; Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Preoperative chemotherapy; Primary chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; LAPATINIB; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PREDNISOLONE; PROGESTERONE RECEPTOR; TRASTUZUMAB; VINBLASTINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; KINESIOTHERAPY; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE;

BIOMARKERS; BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; PREOPERATIVE CHEMOTHERAPY; PRIMARY CHEMOTHERAPY;

ANIMALS; BREAST NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; TREATMENT OUTCOME;

EID: 84885949207     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.02.057     Document Type: Review

References (58)

1. R. Alvarado, M. Yi, H. Le-Petross, M. Gilcrease, E.A. Mittendorf, I. Bedrosian, R.F. Hwang, A.S. Caudle, G.V. Babiera, J.S. Akins, H.M. Kuerer, and K.K. Hunt The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer Ann. Surg. Oncol. 19 2012 3177 3184
2. M. Ayers, W.F. Symmans, J. Stec, A.I. Damokosh, E. Clark, K. Hess, M. Lecocke, J. Metivier, D. Booser, N. Ibrahim, V. Valero, M. Royce, B. Arun, G. Whitman, J. Ross, N. Sneige, G.N. Hortobagyi, and L. Pusztai Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J. Clin. Oncol. 22 2004 2284 2293 (Pubitemid 41115384)
3. C. Balu-Maestro, C. Chapellier, A. Bleuse, I. Chanalet, C. Chauvel, and R. Largillier Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI Breast Cancer Res. Treat. 72 2002 145 152 (Pubitemid 34407209)
4. J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, C. Aura, H. Gomez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T.W. Chang, Z. Horvath, M. Coccia-Portugal, J. Domont, L.M. Tseng, G. Kunz, J.H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R.D. Gelber, and M. Piccart-Gebhart Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
5. J. Baselga, J. Cortes, S.B. Kim, S.A. Im, R. Hegg, Y.H. Im, L. Roman, J.L. Pedrini, T. Pienkowski, A. Knott, E. Clark, M.C. Benyunes, G. Ross, and S.M. Swain Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N. Engl. J. Med. 366 2012 109 119
6. H.D. Bear, S. Anderson, A. Brown, R. Smith, E.P. Mamounas, B. Fisher, R. Margolese, H. Theoret, A. Soran, D.L. Wickerham, and N. Wolmark The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol. 21 2003 4165 4174 (Pubitemid 46606185)
7. H.D. Bear, G. Tang, P. Rastogi, C.E. Geyer Jr., A. Robidoux, J.N. Atkins, L. Baez-Diaz, A.M. Brufsky, R.S. Mehta, L. Fehrenbacher, J.A. Young, F.M. Senecal, R. Gaur, R.G. Margolese, P.T. Adams, H.M. Gross, J.P. Costantino, S.M. Swain, E.P. Mamounas, and N. Wolmark Bevacizumab added to neoadjuvant chemotherapy for breast cancer N. Engl. J. Med. 366 2012 310 320
8. D.A. Berry, K.A. Cronin, S.K. Plevritis, D.G. Fryback, L. Clarke, M. Zelen, J.S. Mandelblatt, A.Y. Yakovlev, J.D. Habbema, and E.J. Feuer Effect of screening and adjuvant therapy on mortality from breast cancer N. Engl. J. Med. 353 2005 1784 1792 (Pubitemid 41549890)
9. T.A. Buchholz, C.D. Lehman, J.R. Harris, B.A. Pockaj, N. Khouri, N.F. Hylton, M.J. Miller, T. Whelan, L.J. Pierce, L.J. Esserman, L.A. Newman, B.L. Smith, H.D. Bear, and E.P. Mamounas Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference J. Clin. Oncol. 26 2008 791 797 (Pubitemid 351265334)
10. A.U. Buzdar, R.C. Coombes, P.E. Goss, and E.P. Winer Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer Cancer 112 2008 700 709 (Pubitemid 351186392)
11. A.U. Buzdar, V. Valero, N.K. Ibrahim, D. Francis, K.R. Broglio, R.L. Theriault, L. Pusztai, M.C. Green, S.E. Singletary, K.K. Hunt, A.A. Sahin, F. Esteva, W.F. Symmans, M.S. Ewer, T.A. Buchholz, and G.N. Hortobagyi Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin. Cancer Res. 13 2007 228 233 (Pubitemid 46121873)
12. L.A. Carey, R. Metzger, E.C. Dees, F. Collichio, C.I. Sartor, D.W. Ollila, N. Klauber-DeMore, J. Halle, L. Sawyer, D.T. Moore, and M.L. Graham American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome J. Natl. Cancer Inst. 97 2005 1137 1142 (Pubitemid 41511213)
13. R.W. Carlson, D.C. Allred, B.O. Anderson, H.J. Burstein, W.B. Carter, S.B. Edge, J.K. Erban, W.B. Farrar, L.J. Goldstein, W.J. Gradishar, D.F. Hayes, C.A. Hudis, M. Jahanzeb, K. Kiel, B.M. Ljung, P.K. Marcom, I.A. Mayer, B. McCormick, L.M. Nabell, L.J. Pierce, E.C. Reed, M.L. Smith, G. Somlo, R.L. Theriault, N.S. Topham, J.H. Ward, E.P. Winer, and A.C. Wolff Breast cancer. Clinical practice guidelines in oncology J. Natl. Compr. Cancer Network 7 2009 122 192
14. J.C. Chang, A. Makris, M.C. Gutierrez, S.G. Hilsenbeck, J.R. Hackett, J. Jeong, M.L. Liu, J. Baker, K. Clark-Langone, F.L. Baehner, K. Sexton, S. Mohsin, T. Gray, L. Alvarez, G.C. Chamness, C.K. Osborne, and S. Shak Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients Breast Cancer Res. Treat. 108 2008 233 240 (Pubitemid 351311356)
15. J.C.N. Chang, I.A. Mayer, A. Forero-Torres, R. Nanda, M.P. Goetz, A.A. Rodriguez, A.C. Pavlick, T. Wang, S.G. Hilsenbeck, C. Gutierrez, R. Schiff, C.K. Osborne, and M.F. Rimawi TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer J. Clin. Oncol. 2011 29 (suppl; abstr 505)
16. B. Chevallier, H. Roche, J.P. Olivier, P. Chollet, and P. Hurteloup Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate Am J. Clin. Oncol. 16 1993 223 228 (Pubitemid 23184384)
17. R.M. Connolly, J.P. Leal, M.P. Goetz, Z. Zhang, X.C. Zhou, J. Mhlanga, S.C. Jeter, B. Walsh, P. Powers, J. Zorzi, J. Carpenter, A.M. Storniolo, S. Watkins, J. Fetting, R. Miller, K. Sideras, N. Khouri, E. Gabrielson, R.L. Wahl, and V. Stearns Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) predicts response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational Breast Cancer Research Consortium (TBCRC008). Presented at the American Society of Clinical Oncology (ASCO) meeting 2012 J. Clin. Oncol. 30 2012 (suppl; abstr 10509)
18. B. Fisher, A. Brown, E. Mamounas, S. Wieand, A. Robidoux, R.G. Margolese, A.B. Cruz Jr., E.R. Fisher, D.L. Wickerham, N. Wolmark, A. DeCillis, J.L. Hoehn, A.W. Lees, and N.V. Dimitrov Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J. Clin. Oncol. 15 1997 2483 2493 (Pubitemid 27289876)
19. B. Fisher, N. Gunduz, J. Coyle, C. Rudock, and E. Saffer Presence of a growth-stimulating factor in serum following primary tumor removal in mice Cancer Res. 49 1989 1996 2001 (Pubitemid 19106503)
20. Food and Drug Administration. Draft Guidance for Industry. Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval (〈http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM305501.pdfa〉).
21. D. Fumagalli, P.L. Bedard, Z. Nahleh, S. Michiels, C. Sotiriou, S. Loi, J.A. Sparano, M. Ellis, N. Hylton, J.A. Zujewski, C. Hudis, L. Esserman, and M. Piccart A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints Lancet Oncol. 13 2012 e240 e248
22. Gamez C., Flamen P., Holmes E., Robles J., Ghebart G., Di Cosimo S., Eidtmann H., Piccart-Gebhart M., J, B. & de Azambuja E. (2011) FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2 positive breast cancer patients: The Neo-ALTTO PET Study Results. Presented at ESMO Meeting September 2011.
23. L. Gianni, T. Pienkowski, Y.H. Im, L. Roman, L.M. Tseng, M.C. Liu, A. Lluch, E. Staroslawska, J de la Haba-Rodriguez, S.A. Im, J.L. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, and P. Valagussa Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol. 13 1 2012 25 32
24. L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vazquez, M. Byakhow, M. Lichinitser, M.A. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, R. Baronio, A. Feyereislova, C. Barton, P. Valagussa, and J. Baselga Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
25. L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, J. Wu, G. Mariani, J. Rodriguez, M. Carcangiu, D. Watson, P. Valagussa, R. Rouzier, W.F. Symmans, J.S. Ross, G.N. Hortobagyi, L. Pusztai, and S. Shak Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J. Clin. Oncol. 23 2005 7265 7277 (Pubitemid 46202341)
26. V. Guarneri, A. Frassoldati, A. Bottini, K. Cagossi, G. Bisagni, S. Sarti, A. Ravaioli, L. Cavanna, G. Giardina, A. Musolino, M. Untch, L. Orlando, F. Artioli, C. Boni, D.G. Generali, P. Serra, M. Bagnalasta, L. Marini, F. Piacentini, R. D'Amico, and P. Conte Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study J. Clin. Oncol. 30 2012 1989 1995
27. M.E. Hammond, D.F. Hayes, M. Dowsett, D.C. Allred, K.L. Hagerty, S. Badve, P.L. Fitzgibbons, G. Francis, N.S. Goldstein, M. Hayes, D.G. Hicks, S. Lester, R. Love, P.B. Mangu, L. McShane, K. Miller, C.K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J.N. Schwartz, F.C. Sweep, S. Taube, E.E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R.B. Williams, J.L. Wittliff, and A.C. Wolff American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J. Clin. Oncol. 28 2010 2784 2795
28. A.W. Hutcheon, S.D. Heys, and T.K. Sarkar Neoadjuvant docetaxel in locally advanced breast cancer Breast Cancer Res. Treat. 79 Suppl 1 2003 S19 S24
29. M. Ignatiadis, S.K. Singhal, C. Desmedt, B. Haibe-Kains, C. Criscitiello, F. Andre, S. Loi, M. Piccart, S. Michiels, and C. Sotiriou Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis J. Clin. Oncol. 30 2012 1996 2004
30. M. Kaufmann, G.N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, A. Lebeau, S. Loibl, W. Miller, S. Seeber, V. Semiglazov, R. Smith, R. Souchon, V. Stearns, M. Untch, and G. von Minckwitz Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J. Clin. Oncol. 24 2006 1940 1949 (Pubitemid 46638994)
31. M. Kaufmann, G. von Minckwitz, H.D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, A. Makris, W. Miller, J.Y. Pierga, V. Semiglazov, A. Schneeweiss, R. Souchon, V. Stearns, M. Untch, and S. Loibl Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann. Oncol. 18 2007 1927 1934 (Pubitemid 350286227)
32. X. Kong, M.S. Moran, N. Zhang, B. Haffty, and Q. Yang Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients Eur. J. Cancer 47 2011 2084 2090
33. H.M. Kuerer, L.A. Newman, T.L. Smith, F.C. Ames, K.K. Hunt, K. Dhingra, R.L. Theriault, G. Singh, S.M. Binkley, N. Sneige, T.A. Buchholz, M.I. Ross, M.D. McNeese, A.U. Buzdar, G.N. Hortobagyi, and S.E. Singletary Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J. Clin. Oncol. 17 1999 460 469 (Pubitemid 29075229)
34. D. Mauri, N. Pavlidis, and J.P. Ioannidis Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J. Natl. Cancer Inst. 97 2005 188 194 (Pubitemid 40277368)
35. S.E. McGuire, A.M. Gonzalez-Angulo, E.H. Huang, S.L. Tucker, S.W. Kau, T.K. Yu, E.A. Strom, J.L. Oh, W.A. Woodward, W. Tereffe, K.K. Hunt, H.M. Kuerer, A.A. Sahin, G.N. Hortobagyi, and T.A. Buchholz Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy Int. J. Radiat. Oncol. Biol. Phys. 68 2007 1004 1009 (Pubitemid 47048565)
36. E.A. Mittendorf, J.S. Jeruss, S.L. Tucker, A. Kolli, L.A. Newman, A.M. Gonzalez-Angulo, T.A. Buchholz, A.A. Sahin, J.N. Cormier, A.U. Buzdar, G.N. Hortobagyi, and K.K. Hunt Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy J. Clin. Oncol. 29 2011 1956 1962
37. R. Peto, C. Davies, J. Godwin, R. Gray, H.C. Pan, M. Clarke, D. Cutter, S. Darby, P. McGale, C. Taylor, Y.C. Wang, J. Bergh, A. Di Leo, K. Albain, S. Swain, M. Piccart, and K. Pritchard Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 2012 432 444
38. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C.H. Barrios, G. Steger, C.S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Lang, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T.M. Suter, J. Ruschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M.S. Dolci, and R.D. Gelber Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N. Engl. J. Med. 353 2005 1659 1672 (Pubitemid 41464705)
39. T.M. Prowell, and R. Pazdur Pathological complete response and accelerated drug approval in early breast cancer N. Engl. J. Med. 366 2012 2438 2441
40. P. Rastogi, S.J. Anderson, H.D. Bear, C.E. Geyer, M.S. Kahlenberg, A. Robidoux, R.G. Margolese, J.L. Hoehn, V.G. Vogel, S.R. Dakhil, D. Tamkus, K.M. King, E.R. Pajon, M.J. Wright, J. Robert, S. Paik, E.P. Mamounas, and N. Wolmark Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J. Clin. Oncol. 26 2008 778 785 (Pubitemid 351264391)
41. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., N.E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P.A. Kaufman, S.M. Swain, T.M. Pisansky, L. Fehrenbacher, L.A. Kutteh, V.G. Vogel, D.W. Visscher, G. Yothers, R.B. Jenkins, A.M. Brown, S.R. Dakhil, E.P. Mamounas, W.L. Lingle, P.M. Klein, J.N. Ingle, and N. Wolmark Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N. Engl. J. Med. 353 2005 1673 1684 (Pubitemid 41464706)
42. D.M. Sataloff, B.A. Mason, A.J. Prestipino, U.L. Seinige, C.P. Lieber, and Z. Baloch Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J. Am. Coll. Surg. 180 1995 297 306
43. W.M. Sikov, D.S. Dizon, R. Strenger, R.D. Legare, K.P. Theall, T.A. Graves, J.S. Gass, T.A. Kennedy, and M.A. Fenton Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study J. Clin. Oncol. 27 2009 4693 4700
44. H.P. Sinn, H. Schmid, H. Junkermann, J. Huober, G. Leppien, M. Kaufmann, G. Bastert, and H.F. Otto [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy] Geburtshilfe Frauenheilkd 54 1994 552 558 (Pubitemid 24351114)
45. I.C. Smith, S.D. Heys, A.W. Hutcheon, I.D. Miller, S. Payne, F.J. Gilbert, A.K. Ah-See, O. Eremin, L.G. Walker, T.K. Sarkar, S.P. Eggleton, and K.N. Ogston Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J. Clin. Oncol. 20 2002 1456 1466 (Pubitemid 34260523)
46. I.E. Smith, M. Dowsett, S.R. Ebbs, J.M. Dixon, A. Skene, J.U. Blohmer, S.E. Ashley, S. Francis, I. Boeddinghaus, and G. Walsh Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J. Clin. Oncol. 23 2005 5108 5116 (Pubitemid 46224019)
47. Sparano, J.A., Wang, M., Martino, S., Jones, V., Perez, E.A., Saphner, T., Wolff, A.C., Sledge, G.W., Wood, W.C. & Davidson, N.E. (2006) Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res. Treat, 88, abstract 48.
48. W.F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, A.U. Buzdar, S.E. Singletary, G.N. Hortobagyi, and L. Pusztai Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J. Clin. Oncol. 25 2007 4414 4422 (Pubitemid 350013847)
49. M. Untch, S. Loibl, J. Bischoff, H. Eidtmann, M. Kaufmann, J.U. Blohmer, J. Hilfrich, D. Strumberg, P.A. Fasching, R. Kreienberg, H. Tesch, C. Hanusch, B. Gerber, M. Rezai, C. Jackisch, J. Huober, T. Kuhn, V. Nekljudova, and G. von Minckwitz Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Lancet Oncol. 13 2012 135 144
50. M. Untch, M. Rezai, S. Loibl, P.A. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kuhn, A. du Bois, J.U. Blohmer, C. Thomssen, S. Dan Costa, C. Jackisch, M. Kaufmann, K. Mehta, and G. von Minckwitz Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J. Clin. Oncol. 28 2010 2024 2031
51. G. von Minckwitz, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, B. Gerber, C. Jackisch, G. Kunz, J.U. Blohmer, J. Huober, M. Hauschild, T. Fehm, B.M. Muller, C. Denkert, S. Loibl, V. Nekljudova, and M. Untch Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer N. Engl. J. Med. 366 2012 299 309
52. G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S.D. Costa, C. Jackisch, S. Loibl, K. Mehta, and M. Kaufmann Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study J. Natl. Cancer Inst. 100 2008 552 562
53. G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S.D. Costa, C. Jackisch, S. Loibl, K. Mehta, and M. Kaufmann Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J. Natl. Cancer Inst. 100 2008 542 551
54. G. von Minckwitz, M. Rezai, S. Loibl, P.A. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kuhn, A. du Bois, J.U. Blohmer, C. Thomssen, S. Dan Costa, C. Jackisch, M. Kaufmann, K. Mehta, and M. Untch Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study J. Clin. Oncol. 28 2010 2015 2023
55. G. von Minckwitz, M. Untch, J.U. Blohmer, S.D. Costa, H. Eidtmann, and PA, Fasching Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol. 30 15 2012 1796 1804
56. Y. Wang, C. Zhang, J. Liu, and G. Huang Is 18 F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis Breast Cancer Res. Treat. 131 2011 357 369
57. N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J. Natl. Cancer Inst. Monogr. 2001 96 102
58. H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra, A.A. Lammertsma, J. Pruim, and P. Price Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur. J. Cancer 35 1999 1773 1782 (Pubitemid 29512308)